Centogene
37 articles with Centogene
-
1Q2019 Life Science Growth Announcements
4/18/2019
In the first quarter of 2019, more than 30 life science companies* announced expansions, new locations, increased funding, new trial and product launches and various other news pointing to a growing industry. -
CENTOGENE Appoints AI Industry Leader Dr. Carsten Ullrich as Director of Artificial Intelligence
4/17/2019
Research Fellow from German Research Center for Artificial Intelligence to lead team driving solutions for pharmaceutical partners
-
CENTOGENE Launches CentoMetabolic™ Panel for Integrated Multiomic Testing for Metabolic Diseases
4/10/2019
Combining genetic and biochemical testing to provide the most comprehensive screening for rare metabolic conditions
-
CENTOGENE announces the appointment of Dr. Flemming Ornskov to the Supervisory Board as Non-Executive Chairman
4/2/2019
CENTOGENE announced that Dr. Flemming Ornskov has been appointed to the Supervisory Board and has been elected Non-Executive Chairman. His appointment is effective April 1, 2019.
-
CENTOGENE Announces Strategic Collaboration with Sarepta Therapeutics
2/28/2019
Agreement focused on identification of patients with Duchenne muscular dystrophy (DMD)
-
CENTOGENE Develops New Validation Framework to Optimize Specificity and Sensitivity in Whole Exome Sequencing-Based Diagnostics
1/30/2019
Since NGS introduces a relevant number of false positives and false negatives, CENTOGENE has determined how to optimize the use of orthogonal Sanger sequencing of variants in parallel when looking at borderline cases.
-
CENTOGENE Expands Clinical Studies Team in U.S.
1/28/2019
Driving Pharmaceutical Partnerships and Accelerating Orphan Drug Development
-
CENTOGENE Receives Prestigious Re-Accreditation by College of American Pathologists
1/24/2019
CENTOGENE’s state-of-the-art genetic laboratory facilities in Rostock, Germany awarded accreditation for the fourth year
-
CENTOGENE Provides Corporate and Business Unit Update
1/8/2019
2018 highlights include expansion to U.S., new partnerships with leading pharmaceutical companies, and growth of diagnostic testing portfolio for rare diseases - driving momentum into 2019
-
CENTOGENE and Chiesi Germany Sign Strategic Alliance in Lysosomal Storage Disorders
12/10/2018
CENTOGENE to perform epidemiology study in Alpha Mannosidosis to support Chiesi’s drug discovery and development
-
CENTOGENE Announces CentoPharma, World’s First Platform for Targeted Patient Cohort Identification
11/16/2018
CENTOGENE today announced the launch of CentoPharma 1.0, the world’s first CE labeled platform for targeted patient cohort identification.
-
CENTOGENE Earns Accreditation to ISO 15189:2012 from CAP
11/8/2018
The College of American Pathologists has awarded CENTOGENE AG accreditation to the ISO15189 standard under the CAP 15189SM Accreditation Program.
-
CENTOGENE Announces Updates to CentoMD®, World’s Largest Genetic Mutation Database of Rare Diseases
11/6/2018
CENTOGENE today announced updates to CentoMD®, the world’s largest genetic mutation database of rare diseases.
-
BioSpace Movers and Shakers Nov. 5
11/5/2018
Biopharma companies make key appointments to fill leadership positions. Let's take a look! -
CENTOGENE Further Expands Executive Team, Appoints Oved Amitay as Chief Business Officer; Increases Focus on Pharma Partnerships
11/2/2018
CENTOGENE, the worldwide leader in elucidating rare disease genetics for patients, clinicians and pharmaceutical partners, today announced the appointment of Oved Amitay as Chief Business Officer.
-
CENTOGENE and Denali Therapeutics Announce Strategic Collaboration to Recruit LRRK2 Patients for Clinical TrialsCENTOGENE to conduct a targeted global identification and recruitment campaign to support Denali´s LRRK2 inhibitor program
10/3/2018
CENTOGENE and Denali Therapeutics (NASDAQ: DNLI) today announced a strategic collaboration for the global identification and recruitment of LRRK2 mutation carrier Parkinson’s disease (“PD”) patients.
-
CENTOGENE and Evotec Sign Global Strategic Partnership on Drug Discovery Projects in Rare Genetic Diseases
8/27/2018
Joint Drug Discovery Projects Combine CENTOGENE’s Patient Access and Biomarker Expertise with Evotec’s Leading iPSC Platform
-
Evotec and Centogene join forces in in rare hereditary metabolic diseases
8/27/2018
Joint drug discovery projects combine CENTOGENE’s patient access and biomarker expertise with Evotec's leading IPSC platform.
-
CENTOGENE Partners with the Universities of Greifswald and Rostock to Develop Fast-Tracked Diagnostic Workflow for Personalized Immune-based Therapies for Colon and Pancreatic Tumors
6/7/2018
CENTOGENE is committed to developing a fast-track diagnostic workflow which lays the groundwork for individualized vaccination therapy in cancer.
-
There are several recent announcements of German companies opening laboratories in the U.S.